文章基本信息

标题：Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
本地全文：下载
作者：Sylvie Dejager ; Anja Schweizer ; James E Foley 等
期刊名称：Vascular Health and Risk Management
印刷版ISSN：1176-6344
电子版ISSN：1178-2048
出版年度：2012
卷号：8
页码：339-348
DOI：10.2147/VHRM.S31758
出版社：Dove Medical Press Ltd
摘要：The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years’ duration in various populations with type 2 diabetes mellitus. This paper reviews the data supporting the use of vildagliptin in monotherapy. Consideration based on baseline glycated hemoglobin levels and age is given to patient segments where metformin is not appropriate. In addition, although prediabetes is not an indication, this manuscript briefly reviews some of the existing data showing that the mechanisms at work in diabetic populations are active in patients currently classified as prediabetic, with impaired glucose tolerance or impaired fasting glucose. Finally, the rationale for vildagliptin dosing frequency in monotherapy is discussed. In summary, this review aims to define where in community practice the use of vildagliptin as monotherapy is most desirable, focusing on segments of the population with type 2 diabetes mellitus that might receive the greatest benefit from vildagliptin in the management of their disease.
关键词：vildagliptin; type 2 diabetes; dipeptidyl peptidase-4 inhibitors; monotherapy; elderly